Skip to content
Brand AI

Catalent

Recent events

Recent events tied to this brand in public sources.

Back to profile21 entries · Page 2 of 2

  1. 2019

    Catalent and Bridge Therapeutics execute exclusive Zydis technology license

    Catalent announced that it had executed an exclusive licensing agreement for Bridge Therapeutics to use Catalent's Zydis orally disintegrating tablet technology. The license initially applies to the United States, with potential to expand to other nations.

    Source